Additional file 6: Table S6. of The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study

Factors associated with specific survival (SS) in 103 Triple-negative canine invasive mammary carcinomas. Univariate (log rank test) and multivariate survival analyses (Cox proportional hazard regression). HR: Hazard Ratio, 95 % CI: 95 % Confidence Interval, IGF1R: Insulin-like Growth Factor type 1 Receptor, LVI: Lymphovascular Invasion. When several significant prognostic factors overlapped, only one was selected for the multivariate analysis (LVI was chosen between lymph node status and LVI because it could have been determined in all cases). (DOC 35 kb

Additional file 1: Table S1. of The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study

Primary antibodies and immunohistochemical protocols (Benchmark XT Ventana, Roche Diagnostics). All dilutions were performed using a commercially available diluent (Ventana Medical Systems). aUltraview and bOptiview Universal DAB detection kit: multimer-technology based detection system. cIView Universal DAB detection kit: biotin streptavidin system. ERα: Estrogen Receptor alpha, PR: Progesterone Receptor, HER2: Epidermal Growth Factor type 2 Receptor, CK5/6: Cytokeratin 5/6, EGFR: Epidermal Growth Factor type 1 Receptor, IGF1R: Insulin-like growth factor type 1 receptor. CC1: Cell Conditioning 1. (DOC 33 kb

Additional file 5: Table S5. of The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study

Factors associated with overall survival (OS) in 103 Triple-negative canine invasive mammary carcinomas. Univariate (log rank test) and multivariate survival analyses (Cox proportional hazard regression). HR: Hazard Ratio, 95 % CI: 95 % Confidence Interval, IGF1R: Insulin-like Growth Factor type 1 Receptor, LVI: Lymphovascular Invasion. When several significant prognostic factors overlapped, only one was selected for the multivariate analysis (LVI was chosen between lymph node status and LVI because it could have been determined in all cases). (DOC 38 kb

Additional file 4: Table S4. of The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study

Factors associated with specific survival (SS) in 47 Luminal canine invasive mammary carcinomas. Univariate (log rank test) and multivariate survival analyses (Cox proportional hazard regression). HR: Hazard Ratio, 95 % CI: 95 % Confidence Interval, HER2: Epidermal Growth Factor type 2 Receptor, IGF1R: Insulin-like Growth Factor type 1 Receptor, LVI: Lymphovascular Invasion. (DOC 33 kb

Additional file 2: Table S2. of The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study

Significant associations between IGF1R expression and clinicopathological features of 47 luminal canine mammary carcinomas. IGF1R score 0–1+ is considered as the reference for each parameter. IGF1R Insulin-like Growth Factor type 1 Receptor. LVI: Lymphovascular Invasion. OR: Odd Ratio. 95 % CI: 95 % Confidence Interval. (DOC 30 kb

Frequency of genomic alterations in the 1p/19q-co-deleted anaplastic oligodendrogliomas on the top part of the panel and non-1p/19q-co-deleted anaplastic oligodendrogliomas on the bottom part.

<p>Panel A. Genomic gain, genomic loss and uniparental disomy are indicated in red, green and blue, respectively. Panel B. High-level amplification and homozygous deletion are indicated in red and green, respectively. Panel C. Genomic breakpoints are indicated with a black dot across the genome.</p

An anaplastic oligodendroglioma with CDKN2A silencing, normal <i>CDKN2A</i> gene copy number status and copy neutral loss of heterozygosity.

<p>Panel A. Top part: Genomic profile with the copy number status. Middle part: Genomic profile with the allelic frequencies. Bottom part: The genomic profile including genomic loss (in green), normal copy number status (light blue) and copy neutral loss of heterozygosity (dark blue). Panel B. Chromosome 9 and the allelic frequencies (the arrow indicates the <i>CDKNA</i> locus). Panel C. Microsatellite analysis showing the allelic status of three markers (D9S1684, D9S171, D9S1121) in the blood DNA (top part) and paired tumor DNA (bottom part). Acquired allelic loss is observed in the tumor DNA Panel D. CDKN2A silenced using immunochemistry.</p

An anaplastic oligodendroglioma with CDKN2A expression and normal <i>CDKN2A</i> gene copy number and allelic statuses.

<p>Panel A. Top part: Genomic profile with the copy number status. Middle part: Genomic profile with the allelic frequencies. Bottom part: The genomic profile including genomic loss (in green), normal copy number status (light blue) and copy neutral loss of heterozygosity (dark blue). Panel B. Chromosome 9 and the allelic frequencies (the arrow indicates the <i>CDKNA</i> locus). Panel C. Microsatellite analysis showing the allelic status of three markers (D9S171 and D9S1121) in the blood DNA (top part) and paired tumor DNA (bottom part) Panel D. CDKN2A expression using immunochemistry.</p

Genomic alterations containing candidate genes in non 1p/19q co-deleted anaplastic oligodendrogliomas in at least two tumors (as identified by genoCN).

<p>Genomic alterations containing candidate genes in non 1p/19q co-deleted anaplastic oligodendrogliomas in at least two tumors (as identified by genoCN).</p

Heat map with genomic profiles of anaplastic oligodendrogliomas.

<p>Each column indicates a tumor. Each row indicates a genomic locus. Tumors were clustered based on the Euclidean distance between their copy number vectors. The color code on the left-upper corner indicates the genomic status: yellow, green and red indicate a normal status, loss and gain, respectively. In addition, the <i>IDH1</i> mutation (pink indicates mutated <i>IDH1</i>/<i>2</i>, while <i>IDH1</i>/<i>2</i> indicates non-mutated <i>IDH1</i>/<i>IDH2</i>), patient age (blue and pink indicate younger and older, respectively, than the median age of the entire population, 49.9 years old) and patient gender (purple indicates male, while brown indicates female) are reported at the top of the figure. The p-value on the right indicates the distribution of the variables between the 1p19q- and non-1p19q-co-deleted tumors. Panel A. 1p/19q-co-deleted anaplastic oligodendrogliomas, with chromosomes 1 and 19 centromeric breakpoints. Panel B. Non-1p/19q co-deleted anaplastic oligodendrogliomas. The legend is the same as the one used in Panel A.</p